Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890189 | 1.00 | THRB (0.46) | THRBALDH1A1TSHR | |
| SCHEMBL504018 | 0.88 | THRB (0.55) | THRBALDH1A1TSHR | |
| SCHEMBL8968 | 0.88 | — | — | |
| SCHEMBL27028519 | 0.88 | THRB (0.55) | THRBALDH1A1TSHR | |
| SCHEMBL16291745 | 0.84 | THRB (0.54) | THRBALDH1A1TSHR | |
| SCHEMBL789340 | 0.82 | — | — | |
| SCHEMBL129302 | 0.82 | — | — | |
| Ammonia Solution, Strong SCHEMBL8694521 | 0.82 | — | — | |
| SCHEMBL21494164 | 0.82 | THRB (0.50) | THRBALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL7537660 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119043-A | Synthesis method of 4,4' - (1, 10-phenanthroline-4, 7-diyl) sodium diphenyl sulfonate | 韶远科技（上海)有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-115974902-B | 2-Cyano-1-phenyl vinyl boric acid pinacol ester and preparation method and application thereof | 韶远科技（上海)有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-114702515-B | Gold (III) complex and application thereof in cancer light therapy | 中山大学 | 2023-08-01 | — | — | CN | claimed |
| EP-2445881-B1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | BOE TECHNOLOGY GROUP CO LTD (CN) | 2017-11-15 | — | — | EP | claimed |
| US-8426601-B2 | Process for making organic compounds and the organic compounds made therefrom | GENERAL ELECTRIC COMPANY (US) | 2013-04-23 | — | — | US | claimed |
| US-20120178938-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2012-07-12 | — | — | US | claimed |
| US-8178682-B2 | Process for making organic compounds and the organic compounds made therefrom | GENERAL ELECTRIC COMPANY (US) | 2012-05-15 | — | — | US | claimed |
| EP-2445881-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | General Electric Company (US) | 2012-05-02 | — | — | EP | claimed |
| US-20100331547-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2010-12-30 | — | — | US | claimed |
| WO-2010151389-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2010-12-29 | — | — | WO | claimed |
| EP-1768988-B1 | NOVEL PHENYL-BORONIC ACID DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | GALDERMA RES & DEV (FR) | 2009-01-28 | — | — | EP | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577254-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | Signal Rx Pharmaceuticals, Inc. | 2026-03-17 | — | — | US | disclosed |
| WO-2002069970-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001032625-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331547-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | CYP4F11, BCL6, CYP2F1 | THRB 1008/4885ALDH1A1 2404/4885TSHR 682/4885 |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | THRB 3314/4885ALDH1A1 384/4885TSHR 2928/4885 |
| US-12577254-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CHEK1, CDK1, CDK3 | THRB 660/4885ALDH1A1 4453/4885TSHR 928/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | THRB 56/4885ALDH1A1 2886/4885TSHR 61/4885 |
| US-20120178938-A1 | PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM | CYP2F1, CYP4F2, CYP1B1 | THRB 3142/4885ALDH1A1 583/4885TSHR 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.